Intensity Therapeutics resumed patient enrollment in Invincible III and Invincible IV, while capital remained the gating factor for Invincible III activation and enrollment speed. Cash and equivalents were $8.5 million as of September 30, 2026.
INTS · Intensity Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, our cash and cash equivalents were approximately $8.5 million. Based on our balances in cash and cash equivalents, our ability to continue our operations is dependent on obtaining additional capital, which is not within our control. As a result, we believe there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.
Intensity Therapeutics resumed INVINCIBLE-3 enrollment in the third quarter of 2026, while INVINCIBLE-4 data showed 71% pCR versus 42% for SOC. Cash was $8.5 million and nine-month net loss was $9.0 million, raising substantial going-concern doubt.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Enrollment resumed in both INVINCIBLE-3 and INVINCIBLE-4, and preliminary INVINCIBLE-4 data showed higher pathological complete response and fewer grade 3 and immune-related adverse events with INT230-6 than with standard of care alone. Net loss increased 33%, operating cash burn is expected to rise, full enrollment remains dependent on capital, and resolution of the revised dosing regimen’s skin issue awaits an independent safety review.
- + Two clinical manuscripts were accepted for peer review, and management reported continuing interest from potential business-development partners. new
- + A new INT230-6 manufacturing batch is expected to be completed in the first quarter of 2027 and is likely to supply both ongoing clinical studies. new
- + INVINCIBLE-3 adopted CHOI density-based response criteria to better assess progression while retaining overall survival as the endpoint. new
- − INVINCIBLE-3 patients had not yet been randomized as of the earnings call. new
- − Full INVINCIBLE-3 enrollment and site activation remained contingent on sufficient incremental funding. new
- − Resolution of the localized skin irritation under the revised INVINCIBLE-4 dosing regimen remained unconfirmed pending an independent safety review expected in the first quarter of 2027. new
- − The new INT230-6 manufacturing batch incurred $162,000 in higher manufacturing costs. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INTS
this stock
Intensity Therapeutics, Inc.
|
$10.17M | — | — | — | 2.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 18
Intensity Therapeutics reported enrollment resumed in INVINCIBLE-3 and INVINCIBLE-4 during the third quarter of 2026. Cash and cash equivalents were $8.5 million as of September 30, 2026, while third-quarter net loss was $3.5 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INTS | +2.7% | -8.1% | -34.2% | -9.4% | -70.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.1% | -6.9% | -34.7% | -9.2% | -80.6% |